$LXRX News

Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy

Lexicon Pharmaceuticals Issues Update On Baseline Characteristics Of Patients Randomized Into Its Ongoing Pivotal Phase 3 SONATA-HCM Clinical Trial Evaluating Sotagliflozin In Patients With Symptomatic Hypertrophic Cardiomyopathy; Patient Enrollment Profile Of SONATA-HCM Is Consistent With Study’s Inclusive Design

Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease

Lexicon Highlights Preclinical Studies Showing Biological Effects Of Sotagliflozin In Hypertrophic Cardiomyopathy And Thrombotic Disease Pathways

Lexicon Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript

Lexicon Pharmaceuticals (LXRX) Stock Fair Value Rises After SONATA HCM Trial Progress

Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM

Cantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8

LX-9211 Market Outlook 2026-2034 | Sales Forecast Highlights Emerging Commercial Opportunities

Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data

Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon

Novo Nordisk (CPSE:NOVO B) Reaches LX9851 Obesity Drug Milestone

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets

Lexicon (LXRX) Q2 2026 Earnings Call Transcript

Lexicon Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

Why Lexicon Pharmaceuticals (LXRX) Is Up 6.9% After Q2 Revenue Collapse And New Shelf Filings